Formulary Search Results for: CALCIUM AND VITAMIN D
9.6.4 Vitamin D - View Category
Restrictions:
These formulations of calcium and vitamin D are restricted to use when Preferred List formulations are not tolerated.
Prescribing Notes:
Calcium and vitamin D tablets, chewable tablets and effervescent tablets are the preferred formulations (see Preferred List).
Please note: Calcium and vitamin D preparations may vary in strength, dosage and frequency
9.6.4 Vitamin D - View Category
Prescribing Notes:
The current preferred calcium and vitamin D preparations in Acute Services and Primary Care are
- Accrete D3 One A Day chewable tablets (once daily) is first-line preparation
- Accrete D3 film-coated tablets (twice daily) is second-line preparation for patients who do not tolerate the first-line preparation. Not suitable for patients with peanut or soybean allergy, and patients requiring a gelatin free preparation.
- Adcal D3 Dissolve effervescent tablets (twice daily) preparation of choice for patients with swallowing difficulties or who have enteral tubes.
- Adcal D3 chewable tablets are available for oncology patients to reflect oncology protocols. Not suitable for patients with peanut or soybean allergy, and patients requiring a gelatin free preparation.
Please note: Calcium and vitamin D preparations may vary in strength, dosage and frequency.
9.6.4 Vitamin D - View Category
Restrictions:
Excludes Fultium D3 3,200 unit strength. Invita D3 oral ampoules are restricted to use only when other oral vitamin D preparations are not suitable.
Prescribing Notes:
For NHSGGC guidance on when to measure vitamin D levels and the subsequent management of vitamin D deficiency and insufficiency click here. Also see the Prescribing Resources page for further useful documents.
Vitamin D supplementation usually falls into two broad categories, low dose supplementation and high dose supplementation. Low dose is considered to be doses of 1,000 units daily or less and is used most often for supplementation in insufficiency states. High dose vitamin D is considered to be doses in excess of 20,000 units per week. High dose vitamin D is more likely to be used in deficiency states leading to morbidity.
1.3.5 Proton pump inhibitors - View Category
Restrictions:
Use is restricted to
- patients with narrow-bore feeding tubes
- patients in the immediate period (2 weeks) after barriatric surgery
Prescribing Notes:
The orodispersible preparations are considerably more expensive than omeprazole capsules and should not used unless necessary.
1.6.2 Stimulant laxatives - View Category
12.1.2 Otitis media - View Category
Restrictions:
Restricted to use in the treatment of acute otitis media in patients with tympanostomy tubes (AOMT).
12.2.1 Drugs used in nasal allergy - View Category
11.4.1 Eye-corticosteroids - View Category
Restrictions:
Macular Oedema: Restricted to specialist use in adult patients with macular oedema following central retinal vein occlusion (CRVO) and in patients with branch retinal vein occlusion (BRVO) who are not clinically suitable for laser treatment including patients with dense macular haemorrhage or patients who have received and failed on previous laser treatment in accordance with local protocol.
Diabetic Macular Oedema: Use in the treatment of adults with visual impairment due to diabetic macular oedema who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy, is restricted to specialist use only.
Non-infectious Uveitis: Use for the treatment of non-infectious uveitis is restricted to specialist use in accordance with NICE TA460.
11.6.1 Beta - blockers - View Category
Restrictions:
Restricted to specialist initiation.
Prescribing Notes:
The preserved eye drops are the first choice preparation. However, long-acting preparations of timolol should be reserved only for patients with compliance issues. For preservative-free preparations of timolol, see the Total Formulary